

APPLICANTS: Vickers et al.
SERIAL NO: 10/664,639

DOCKET NO: CORE0027US

AMENDMENTS TO THE SPECIFICATION:

Please replace paragraph [000197] with the following:

The antisense oligoribonucleotides of the present invention were used to treat T24 cells, and the *in vitro* activity of these oligomeric compounds was characterized. T24 cells were dosed at concentrations ranging from 50 to 200 nM antisense oligoribonucleotide (asRNA), and PTEN target mRNA levels were compared to levels in untreated control cells. Chemical modifications were made to ISIS 303912 and compared to the parent compound for their ability to reduce mRNA levels in T24 cells. ISIS 316449 (which represents ISIS 303912 with three ~~2'-O-methoxyethyl~~ (2'-O-methyl) 2'-O-methyl modifications on the 3' end and a 5' terminal phosphate) and ISIS 319022 (which represents ISIS 303912 having fully modified 2'-F modifications throughout and a 5' terminal phosphate) were compared to ISIS 303912 also having a 5' terminal phosphate. As shown in Table V, ISIS 303912, (SEQ ID NO: 112) UUUGUCUCUGGUCCUUACUU, as well as ISIS 316449 and ISIS 319022, was ~~all~~ were found to exhibit dose responsive inhibition of PTEN mRNA levels.